Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H23NO3 |
| Molecular Weight | 289.3694 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC[C@H]1CC[C@@H](CC1)C(=O)C2=CC=C(CCC(O)=O)C=C2
InChI
InChIKey=NVBZUCIQNYPGCI-CTYIDZIISA-N
InChI=1S/C17H23NO3/c18-11-13-3-8-15(9-4-13)17(21)14-6-1-12(2-7-14)5-10-16(19)20/h1-2,6-7,13,15H,3-5,8-11,18H2,(H,19,20)/t13-,15-
Rotraxate (also known as TEI 5103 or TG 51) is an anti-ulcerative agent. Experiments on rodents have shown that only the oral and gastric route of administration lead to the anti-ulcer effect. This drug increased gastric mucosal blood flow and possibly promoted the healing process of peptic ulcers. However, the further development of this drug was discontinued.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effect of 3-[p-(trans-4-aminomethylcyclohexylcarbonyl)phenyl] propionic acid hydrochloride on gastric mucosa directly from the lumen. | 1987-11 |
|
| Effect of 3-[p-(trans-4-aminomethylcyclohexylcarbonyl)-phenyl] propionic acid hydrochloride on gastric mucosal blood flow. | 1987-11 |
|
| Effect of 3-[p-(trans-4-aminomethylcyclohexylcarbonyl)phenyl]propionic acid hydrochloride on gastric mucosal barrier. | 1987-10 |
|
| Crystal and molecular structures of a new anti-ulcer agent, 3-[p-(trans-4-aminomethylcyclohexylcarbonyl)phenyl]propionic acid hydrochloride. | 1986-09 |
|
| Anti-ulcer effect of 3-[p-(trans-4-aminomethylcyclohexylcarbonyl) phenyl] propionic acid hydrochloride (TEI-5103). | 1985 |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29701
Created by
admin on Mon Mar 31 18:30:13 GMT 2025 , Edited by admin on Mon Mar 31 18:30:13 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
6066
Created by
admin on Mon Mar 31 18:30:13 GMT 2025 , Edited by admin on Mon Mar 31 18:30:13 GMT 2025
|
PRIMARY | |||
|
SUB10393MIG
Created by
admin on Mon Mar 31 18:30:13 GMT 2025 , Edited by admin on Mon Mar 31 18:30:13 GMT 2025
|
PRIMARY | |||
|
m920
Created by
admin on Mon Mar 31 18:30:13 GMT 2025 , Edited by admin on Mon Mar 31 18:30:13 GMT 2025
|
PRIMARY | Merck Index | ||
|
100000084364
Created by
admin on Mon Mar 31 18:30:13 GMT 2025 , Edited by admin on Mon Mar 31 18:30:13 GMT 2025
|
PRIMARY | |||
|
DTXSID901017463
Created by
admin on Mon Mar 31 18:30:13 GMT 2025 , Edited by admin on Mon Mar 31 18:30:13 GMT 2025
|
PRIMARY | |||
|
3826
Created by
admin on Mon Mar 31 18:30:13 GMT 2025 , Edited by admin on Mon Mar 31 18:30:13 GMT 2025
|
PRIMARY | |||
|
CHEMBL2105418
Created by
admin on Mon Mar 31 18:30:13 GMT 2025 , Edited by admin on Mon Mar 31 18:30:13 GMT 2025
|
PRIMARY | |||
|
65829
Created by
admin on Mon Mar 31 18:30:13 GMT 2025 , Edited by admin on Mon Mar 31 18:30:13 GMT 2025
|
PRIMARY | |||
|
C76490
Created by
admin on Mon Mar 31 18:30:13 GMT 2025 , Edited by admin on Mon Mar 31 18:30:13 GMT 2025
|
PRIMARY | |||
|
92071-51-7
Created by
admin on Mon Mar 31 18:30:13 GMT 2025 , Edited by admin on Mon Mar 31 18:30:13 GMT 2025
|
PRIMARY | |||
|
KRN50N3Y2T
Created by
admin on Mon Mar 31 18:30:13 GMT 2025 , Edited by admin on Mon Mar 31 18:30:13 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
